Clinical trials for - Crohn’s Disease

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44393 clinical trials with a EudraCT protocol, of which 7405 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (28,525)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

28,525 result(s) found for: - Crohn’s Disease. Displaying page 737 of 1,427.

EudraCT Number: 2015-001503-31

Sponsor Protocol Number: RD.03.SPR.105078

Start Date*: 2015-11-30

Sponsor Name:Galderma R&D

Full Title: Subject adherence and satisfaction for treatment of Onychomycosis with Loceryl® Nail Lacquer 5% versus Canesten® Fungal Nail Treatment Set

Medical condition: Mycological confirmed toenail Distal and Lateral Subungual Onychomycosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	10021881 - Infections and infestations	10030338	Onychomycosis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IS (Completed)

Trial results: View results

EudraCT Number: 2015-001464-19

Sponsor Protocol Number: GE-122-020

Start Date*: 2016-02-11

Sponsor Name:GE Healthcare Ltd. and its affiliates

Full Title: AdreView™ Myocardial Imaging for Risk Evaluation – A multicentre trial to guide ICD implantation in NYHA class II & III heart failure patients with 30%≤LVEF≤35% ADMIRE-ICD

Medical condition: Heart failure

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.1	100000004849	10064081	Heart failure NYHA class III	LLT
	18.1	100000004849	10064080	Heart failure NYHA class II	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended)

Trial results: View results

EudraCT Number: 2015-002996-12

Sponsor Protocol Number: GS-US-367-1173

Start Date*: 2016-02-16

Sponsor Name:Gilead Sciences, Inc.

Full Title: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir f...

Medical condition: Chronic Hepatitis C virus infection

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.1	10021881 - Infections and infestations	10019744	Hepatitis C	PT
	18.1	10021881 - Infections and infestations	10008912	Chronic hepatitis C	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) GB (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2017-001677-16

Sponsor Protocol Number: RD.03.SPR.104003

Start Date*: 2018-04-05

Sponsor Name:Galderma S.A.

Full Title: A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous...

Medical condition: Cutaneous T Cell Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	22.0	100000004864	10028483	Mycosis fungoides	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2018-003113-17

Sponsor Protocol Number: MEU17/361

Start Date*: 2018-11-09

Sponsor Name:The Medicines Evaluation Unit (MEU) Ltd. (Investigator led study)

Full Title: A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation...

Medical condition: Chronic obstructive pulmonary disease (COPD)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004855	10010952	COPD	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2017-003792-63

Sponsor Protocol Number: UCL/17/0629

Start Date*: 2018-10-23

Sponsor Name:University College London

Full Title: Phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer

Medical condition: recurrent ovarian/fallopian tube or primary non-mucinous peritoneal cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016180	Fallopian tube cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2007-002589-37

Sponsor Protocol Number: SL0008

Start Date*: 2008-07-17

Sponsor Name:UCB Inc

Full Title: A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease Who Parti...

Medical condition: systemic lupus erythematosus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10042945	Systemic lupus erythematosus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) LT (Completed) HU (Completed) BE (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2010-018565-26

Sponsor Protocol Number: SL0010

Start Date*: 2011-01-16

Sponsor Name:UCB Inc.

Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab in systemic lupus erythematosu...

Medical condition: Systemic Lupus Erythmatosus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10028395 - Musculoskeletal and connective tissue disorders	10042945	Systemic lupus erythematosus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed) ES (Completed) DE (Completed) GB (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2010-021886-63

Sponsor Protocol Number: RD2010-48

Start Date*: 2011-07-14

Sponsor Name:East and North Hertfordshire NHS Trust [...]

Full Title: A trial of Prostate Radiotherapy in Conjunction with Carbogen and Nicotinamide (PROCON)

Medical condition: Prostate Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10060862	Prostate cancer	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: GB (Completed)

Trial results: (No results available)

EudraCT Number: 2011-001987-24

Sponsor Protocol Number: D3820C00004

Start Date*: 2011-08-22

Sponsor Name:AstraZeneca AB

Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

Medical condition: Opioid-induced constipation (OIC)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10017947 - Gastrointestinal disorders	10010774	Constipation	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) SK (Completed)

Trial results: View results

EudraCT Number: 2011-001735-22

Sponsor Protocol Number: CNTO328SMM2001

Start Date*: 2011-09-28

Sponsor Name:Janssen-Cilag International N.V.

Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma

Medical condition: High-risk Smoldering Multiple Myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	100000004864	10028233	Multiple myeloma without mention of remission	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) GB (Completed) SE (Completed) FR (Completed) GR (Completed) ES (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2011-004631-31

Sponsor Protocol Number: REM-PH-416

Start Date*: 2012-03-13

Sponsor Name:United Therapeutics Corp.

Full Title: A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects with Pul...

Medical condition: Pulmonary Arterial Hypertension (PAH)

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10038738 - Respiratory, thoracic and mediastinal disorders	10064911	Pulmonary arterial hypertension	PT
	14.1	10038738 - Respiratory, thoracic and mediastinal disorders	10065151	Idiopathic pulmonary arterial hypertension	LLT
	14.1	10038738 - Respiratory, thoracic and mediastinal disorders	10065152	Familial pulmonary arterial hypertension	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2011-002545-35

Sponsor Protocol Number: OCTO_026

Start Date*: 2012-01-23

Sponsor Name:University of Oxford

Full Title: A randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma

Medical condition: Advanced/metastatic melanoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10027481	Metastatic melanoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2012-003141-16

Sponsor Protocol Number: HEM2012BL01

Start Date*: 2012-10-18

Sponsor Name:VU University Medical Center

Full Title: Efficacy and feasibility of first-line treatment with risk-adapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients with Burkitt lymphoma. A phase II clinical trial.

Medical condition: Burkitt lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10005329 - Blood and lymphatic system disorders	10006596	Burkitt's lymphomas	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2012-003510-13

Sponsor Protocol Number: IRST174.08

Start Date*: 2013-05-07

Sponsor Name:IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI

Full Title: A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/A...

Medical condition: pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.1	100000004864	10027475	Metastatic breast cancer	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2013-003545-41

Sponsor Protocol Number: D1344C00001

Start Date*: 2014-04-14

Sponsor Name:AstraZeneca AB

Full Title: A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic...

Medical condition: Metastatic uveal melanoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025654	Malignant melanoma of sites other than skin	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Completed) NL (Completed) FI (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2014-000242-30

Sponsor Protocol Number: CNTO148PSA3001

Start Date*: 2014-12-29

Sponsor Name:Janssen Biologics, BV

Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Psoriatic Arthritis

Medical condition: Psoriatic Arthritis (PsA)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004859	10037160	Psoriatic arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) LT (Completed) ES (Completed) HU (Completed)

Trial results: View results

EudraCT Number: 2009-013408-30

Sponsor Protocol Number: 2009-013408-30

Start Date*: 2010-08-23

Sponsor Name:University College London

Full Title: Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancers

Medical condition: biliary tract carcinomas (including gallbladder cancer and cholangiocarcinomas)

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.0	100000004864	10004595	Bile duct cancer NOS	LLT
	17.0	100000004864	10008594	Cholangiocarcinoma non-resectable	LLT
	17.0	100000004864	10017617	Gallbladder cancer non-resectable	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2015-003167-10

Sponsor Protocol Number: GS-US-367-1170

Start Date*: 2016-02-16

Sponsor Name:Gilead Sciences, Inc.

Medical condition: Chronic Hepatitis C virus infection

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.1	10021881 - Infections and infestations	10019744	Hepatitis C	PT
	18.1	10021881 - Infections and infestations	10008912	Chronic hepatitis C	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) FR (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2016-001356-22

Sponsor Protocol Number: CLR_09_21

Start Date*: 2016-07-13

Sponsor Name:Sun Pharma Advanced Research Company Ltd.

Full Title: A PLACEBO-CONTROLLED RANDOMIZED WITHDRAWAL EVALUATION OF THE EFFICACY AND SAFETY OF BACLOFEN ER CAPSULES (GRS) IN SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS

Medical condition: Spasticity due to multiple sclerosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004852	10041416	Spasticity	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Thu Apr 09 17:35:50 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA